Related Experiment Video
Updated: Jul 3, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
Nociceptin/orphanin FQ peptide receptor as a therapeutic target for obesity
Magdalena J Przydzial1, Lora K Heisler
1Department of Pharmacology, Tennis Court Road, University of Cambridge, Cambridge, CB2 1PD UK.
Abstract:
Nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor is a candidate target for novel therapeutics for a range of conditions, including obesity. This article reviews recent advances in understanding of N/OFQ's involvement in the regulation of food intake and appraises current developments in the rational design of antagonists aimed at the NOP receptor.
Insights
The nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor shows promise for treating obesity. Research is advancing the design of NOP receptor antagonists to regulate food intake.
Area of Science:
- Neuroscience
- Pharmacology
- Endocrinology
Background:
- The nociceptin/orphanin FQ (N/OFQ) peptide acts through the NOP receptor.
- The NOP receptor system is implicated in regulating physiological processes, including appetite.
Purpose of the Study:
- To review recent findings on the role of N/OFQ in food intake regulation.
- To assess the progress in developing NOP receptor antagonists for therapeutic applications.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of drug design strategies targeting the NOP receptor.
Main Results:
- N/OFQ signaling influences appetite control.
- Several classes of NOP receptor antagonists are under investigation.
- Rational drug design is yielding promising compounds.
Conclusions:
- The NOP receptor is a viable therapeutic target for obesity and other conditions.
- Further development of NOP receptor antagonists could lead to novel treatments for appetite dysregulation.
Related Concept Videos
Regulation of Food Intake
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Nociception
Obesity

